Lpilimumab, a monoclonal antibody directed to the immune checkpoint receptor termed “cytotoxic T lymphocyte antgen-4 (CTLA-4)”, received FDA approval for treatment of metastatic melanoma in March 2011. Here, CTLA4 is linked to metastatic melanoma.